MARKET

PDLI

PDLI

PDL BioPharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.260
-0.020
-0.61%
Opening 10:16 08/14 EDT
OPEN
3.280
PREV CLOSE
3.280
HIGH
3.285
LOW
3.260
VOLUME
62.05K
TURNOVER
--
52 WEEK HIGH
3.520
52 WEEK LOW
1.680
MARKET CAP
371.58M
P/E (TTM)
-4.1555
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PDLI stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

PDLI News

More
PDL Biopharma Enters Into Settlement Agreement With Wellstat; Wellstat Parties To Pay $7.5M Upon Signing Of Deal And Either $5M By Feb. 10, 2021 And $55M By July 26, 2021; Or $67.5M By July 26, 2021
Benzinga · 2d ago
PDL BioPharma EPS misses by $0.21, misses on revenue
PDL BioPharma (NASDAQ:PDLI): Q2 GAAP EPS of -$0.11 misses by $0.21. Revenue of $5.21M (-30.2% Y/Y) misses by $26.69M. Press Release
seekingalpha · 08/07 01:13
PDL BioPharma Reports 2020 Second Quarter Financial Results
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2020 and provides an update on important milestones achieved in the execution of its monetization plan:
PR Newswire · 08/06 20:05
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
Benzinga · 08/06 12:57
A Stock-Picker's Guide To Benjamin Graham's Screening Rules
Seeking Alpha · 08/01 09:46
PDL BioPharma Reports Deal To Sell Noden Pharma Business To Stanley Capital For $48.25M In Cash
Benzinga · 07/30 12:33
PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively "Noden") to Stanley Capital
PR Newswire · 07/30 12:30
Hedge Funds Are Selling PDL BioPharma Inc. (PDLI)
Insider Monkey · 06/27 19:26

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
-0.15%

Hot Stocks

Symbol
Price
%Change

About PDLI

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
More

Webull offers kinds of PDL BioPharma Inc stock information, including NASDAQ:PDLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDLI stock methods without spending real money on the virtual paper trading platform.